Delaying Lymph Node Biopsy After Melanoma Diagnosis Does Not Affect Survival Rates

(July 20, 2017)

A lymph node biopsy occurring more than 30 days after diagnosis is unlikely to have an adverse effect on the patient’s overall prognosis Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn’t adversely impact long-term... Continue Reading


New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style

(July 19, 2017)

Two thirds of cancers are unavoidable even if you live a healthy life, according to a study published by doctors from John Hopkins.  The research, published in the journal Science, indicates that the majority of cancer-causing mutations are due to DNA... Continue Reading


FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer

(July 18, 2017)

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the... Continue Reading


Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

(July 18, 2017)

A clinical trial evaluating Opdivo  (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection has demonstrated a superior recurrence-free survival in... Continue Reading


Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know

(July 17, 2017)

The purpose of precision cancer medicine is not to categorize or classify cancers solely by site of origin, but to define the genomic alterations in the cancer’s DNA that are driving that specific cancer.  Precision cancer medicine utilizes molecular... Continue Reading


Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift

(July 13, 2017)

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated... Continue Reading


Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

(July 12, 2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become... Continue Reading


Is Lynparza a Precision Cancer Medicine for Prostate Cancer?

(July 12, 2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing... Continue Reading


Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising

(July 11, 2017)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking... Continue Reading


First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients

(July 6, 2017)

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics... Continue Reading


SUNSHINE: Vitamin D Slows Colon Cancer Progression

(July 6, 2017)

The first-ever completed comparative clinical trial of the use of vitamin D as a colorectal cancer therapy has shown that disease progression is slowed with high-dose supplements according to lead author Kimmie Ng, MD, of the Dana Farber Cancer Institute... Continue Reading


Ovarian Cancer Clinical Trials: What, Where, Why

(July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading


Next Page »